First Time Loading...

Castle Biosciences Inc
NASDAQ:CSTL

Watchlist Manager
Castle Biosciences Inc Logo
Castle Biosciences Inc
NASDAQ:CSTL
Watchlist
Price: 22.625 USD 2.75%
Updated: May 2, 2024

Intrinsic Value

CSTL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. [ Read More ]

The intrinsic value of one CSTL stock under the Base Case scenario is 33.405 USD. Compared to the current market price of 22.625 USD, Castle Biosciences Inc is Undervalued by 32%.

Key Points:
CSTL Intrinsic Value
Base Case
33.405 USD
Undervaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Castle Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CSTL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Castle Biosciences Inc

Provide an overview of the primary business activities
of Castle Biosciences Inc.

What unique competitive advantages
does Castle Biosciences Inc hold over its rivals?

What risks and challenges
does Castle Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in Castle Biosciences Inc recently?

Summarize the latest earnings call
of Castle Biosciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Castle Biosciences Inc.

Provide P/S
for Castle Biosciences Inc.

Provide P/E
for Castle Biosciences Inc.

Provide P/OCF
for Castle Biosciences Inc.

Provide P/FCFE
for Castle Biosciences Inc.

Provide P/B
for Castle Biosciences Inc.

Provide EV/S
for Castle Biosciences Inc.

Provide EV/GP
for Castle Biosciences Inc.

Provide EV/EBITDA
for Castle Biosciences Inc.

Provide EV/EBIT
for Castle Biosciences Inc.

Provide EV/OCF
for Castle Biosciences Inc.

Provide EV/FCFF
for Castle Biosciences Inc.

Provide EV/IC
for Castle Biosciences Inc.

Show me price targets
for Castle Biosciences Inc made by professional analysts.

What are the Revenue projections
for Castle Biosciences Inc?

How accurate were the past Revenue estimates
for Castle Biosciences Inc?

What are the Net Income projections
for Castle Biosciences Inc?

How accurate were the past Net Income estimates
for Castle Biosciences Inc?

What are the EPS projections
for Castle Biosciences Inc?

How accurate were the past EPS estimates
for Castle Biosciences Inc?

What are the EBIT projections
for Castle Biosciences Inc?

How accurate were the past EBIT estimates
for Castle Biosciences Inc?

Compare the revenue forecasts
for Castle Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Castle Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Castle Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Castle Biosciences Inc compared to its peers.

Compare the P/E ratios
of Castle Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Castle Biosciences Inc with its peers.

Analyze the financial leverage
of Castle Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Castle Biosciences Inc.

Provide ROE
for Castle Biosciences Inc.

Provide ROA
for Castle Biosciences Inc.

Provide ROIC
for Castle Biosciences Inc.

Provide ROCE
for Castle Biosciences Inc.

Provide Gross Margin
for Castle Biosciences Inc.

Provide Operating Margin
for Castle Biosciences Inc.

Provide Net Margin
for Castle Biosciences Inc.

Provide FCF Margin
for Castle Biosciences Inc.

Show all solvency ratios
for Castle Biosciences Inc.

Provide D/E Ratio
for Castle Biosciences Inc.

Provide D/A Ratio
for Castle Biosciences Inc.

Provide Interest Coverage Ratio
for Castle Biosciences Inc.

Provide Altman Z-Score Ratio
for Castle Biosciences Inc.

Provide Quick Ratio
for Castle Biosciences Inc.

Provide Current Ratio
for Castle Biosciences Inc.

Provide Cash Ratio
for Castle Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Castle Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Castle Biosciences Inc?

What is the current Free Cash Flow
of Castle Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Castle Biosciences Inc.

Financials

Balance Sheet Decomposition
Castle Biosciences Inc

Current Assets 295.6m
Cash & Short-Term Investments 243.1m
Receivables 38.3m
Other Current Assets 14.2m
Non-Current Assets 157.7m
PP&E 37.7m
Intangibles 117.3m
Other Non-Current Assets 2.6m
Current Liabilities 47.7m
Accounts Payable 10.3m
Accrued Liabilities 33.9m
Other Current Liabilities 3.5m
Non-Current Liabilities 14.4m
Long-Term Debt 25k
Other Non-Current Liabilities 14.4m
Efficiency

Earnings Waterfall
Castle Biosciences Inc

Revenue
219.8m USD
Cost of Revenue
-45m USD
Gross Profit
174.8m USD
Operating Expenses
-242.8m USD
Operating Income
-68m USD
Other Expenses
10.5m USD
Net Income
-57.5m USD

Free Cash Flow Analysis
Castle Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CSTL Profitability Score
Profitability Due Diligence

Castle Biosciences Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
ROIC is Increasing
Exceptional 1-Year Revenue Growth
34/100
Profitability
Score

Castle Biosciences Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

CSTL Solvency Score
Solvency Due Diligence

Castle Biosciences Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Castle Biosciences Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CSTL Price Targets Summary
Castle Biosciences Inc

Wall Street analysts forecast CSTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CSTL is 33.773 USD with a low forecast of 28.28 USD and a high forecast of 38.85 USD.

Lowest
Price Target
28.28 USD
25% Upside
Average
Price Target
33.773 USD
49% Upside
Highest
Price Target
38.85 USD
72% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CSTL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CSTL Price
Castle Biosciences Inc

1M 1M
+2%
6M 6M
+36%
1Y 1Y
+3%
3Y 3Y
-66%
5Y 5Y
+6%
10Y 10Y
+6%
Annual Price Range
22.625
52w Low
11.66
52w High
26
Price Metrics
Average Annual Return 19.47%
Standard Deviation of Annual Returns 73.59%
Max Drawdown -88%
Shares Statistics
Market Capitalization 616.7m USD
Shares Outstanding 27 587 100
Percentage of Shares Shorted 5.45%

CSTL Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Castle Biosciences Inc Logo
Castle Biosciences Inc

Country

United States of America

Industry

Health Care

Market Cap

616.7m USD

Dividend Yield

0%

Description

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.

Contact

TEXAS
Friendswood
505 S Friendswood Drive, Suite 401
+18667889007.0
http://www.castlebiosciences.com/

IPO

2019-07-25

Employees

342

Officers

Founder, CEO, President & Director
Mr. Derek J. Maetzold
CFO & Treasurer
Mr. Frank Stokes
Chief Operating Officer
Ms. Kristen M. Oelschlager R.N.
Chief Commercial Officer
Mr. Tobin W. Juvenal
Vice President of Investor Relations & Corporate Affairs
Camilla Zuckero
Senior Vice President of Marketing
Ms. Alice Bahner Izzo
Show More
Vice President of Sales
Mr. Kevin Doman
VP of Human Resources & Executive Director of Human Resources
Ms. Keli Greenberg
Senior Vice President of Research & Development
Dr. Robert W. Cook Ph.D.
Senior Vice President of Medical
Dr. Matthew Goldberg M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CSTL stock?

The intrinsic value of one CSTL stock under the Base Case scenario is 33.405 USD.

Is CSTL stock undervalued or overvalued?

Compared to the current market price of 22.625 USD, Castle Biosciences Inc is Undervalued by 32%.